On September 8, 2022 Servier reported The ESMO (Free ESMO Whitepaper) (European Society for Medical Oncology) 2022 Congress is taking place from September 9 to 13 in Paris and brings together more than 25,000 oncology professionals from over 160 countries around the world (Press release, Servier, SEP 8, 2022, View Source [SID1234619264]). This is an opportunity for Servier to present its R&D pipeline and new study data in the field of gastrointestinal cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
No less than 40 oncology projects are currently under development at Servier, focused on difficult-to-treat cancers, for targeted populations, and which respond to a high unmet medical need among patients.
In the field of solid tumors, Servier is developing treatments that target gastrointestinal cancers – Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma (a rare and aggressive bile-duct cancer) – and low-grade glioma (brain tumor). In hematology, the Group is continuing its research into certain types of leukemia, such as Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Lymphoma.
Claude Bertrand, Executive Vice President Research and Development of the Servier Group, said: "ESMO is a major international congress where we can share and discuss our latest scientific and medical advances in oncology with the scientific community. Five years after making our strategic commitment to the fight against cancer, this conference allows us to highlight the progress made by the Group, our teams, and our partners in developing therapeutic solutions to treat patients with hard-to-treat cancers."
Servier’s oncology R&D programs focus on two approaches: Immuno-Oncology, which aims to mobilize the immune system against cancer cells, and targeted therapies, which use precision medicine.